Abstract

Bibliographic details

Thompson MF, Chen L, Tangirala M, Asmar L, Jones SE.  Cost-effectiveness of docetaxel-cyclophosphamide versus doxorubicin-cyclophosphamide for breast cancer. American Journal of Pharmacy Benefits 2011; 3(5): 276-283

Status

This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Indexing status

Subject indexing assigned by CRD

Index terms

Breast Neoplasms; Cyclophosphamide; Doxorubicin; Humans; Taxoids

Record category

Clinical